Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.

Feltes TF, Sondheimer HM, Tulloh RM, Harris BS, Jensen KM, Losonsky GA, Griffin MP; Motavizumab Cardiac Study Group.

Pediatr Res. 2011 Aug;70(2):186-91. doi: 10.1203/PDR.0b013e318220a553.

PMID:
21522037
2.

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.

Carbonell-Estrany X, Simões EA, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA; Motavizumab Study Group.

Pediatrics. 2010 Jan;125(1):e35-51. doi: 10.1542/peds.2008-1036. Epub 2009 Dec 14.

PMID:
20008423
3.

[Kawasaki disease--personal observations].

Dylewska K, Maćkowska K, Masłowska E, Kojro-Wojcieszonek A, Balcar-Boroń A.

Wiad Lek. 2001;54(3-4):215-8. Polish.

PMID:
11436689

Supplemental Content

Loading ...
Support Center